The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1118
November 12, 2001
View Complete Issue         Table of Contents 2019 
Nesiritide For Decompensated Congestive Heart Failure
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Nesiritide For Decompensated Congestive Heart Failure
November 12, 2001 (Issue: 1118)
Nesiritide, a recombinant human B-type natriuretic peptide (BNP), has been approved by the FDA of intravenous (IV) treatment of patients with decompensated congestive heart failure who have dyspnea at rest or with minimal exertion (New York Heart...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Nesiritide For Decompensated Congestive Heart Failure
Article code: 1118b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.